Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + capecitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of docetaxel, capecitabine, and cisplatin. Docetaxel is a taxane that promotes the assembly of tubulin into stable microtubules and inhibits their disassembly, leading to a decrease in free tubulin and the inhibition of mitosis. Capecitabine is an orally administered systemic prodrug of 5'-deoxy-5-fluorouridine (5'-DFUR) which is converted to 5-fluorouracil; it inhibits DNA synthesis by blocking the methylation of deoxyuridylic acid to thymidylic acid via thymidylate synthase. Cisplatin is a platinum-based cytotoxic agent that forms DNA adducts, primarily intra-strand cross-links, which inhibit DNA replication and transcription, ultimately leading to programmed cell death. This specific combination was studied by the Roswell Park Cancer Institute in a Phase I trial for patients with advanced or metastatic solid tumors.
- Brand names
- TaxotereXelodaPlatinol
- Other names
- DCC regimenDocetaxel-Capecitabine-Cisplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on docetaxel + capecitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + capecitabine + cisplatin.